Skip to content

The mechanism whereby an exogenous ketone drink lowers blood glucose

The mechanism whereby an exogenous ketone drink lowers blood glucose

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN16169021
Enrollment
10
Registered
2018-03-11
Start date
2018-06-30
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glucose and ketone bodies metabolism Not Applicable

Interventions

Ten healthy participants will be asked to fast for 24 hours before their visit. On their visit to the Department of Physiology and Genetics of the University of Oxford, they will be asked to consume a

Sponsors

TdeltaS Ltd
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Participants must be fluent in English, have no communication impairments and should be willing and able to give informed consent for participation in the trial 2. Aged 18 – 70 (inclusive) 3. With no known medical diagnosis 4. Have had no course of medication, whether prescribed or over-the-counter, in the four weeks before the first trial dose and no individual doses in the final two weeks other than over the counter analgesics, vitamins and mineral supplements or, for females, oral contraceptives 5. Female participants of childbearing potential and male participants whose partner is of childbearing potential must be willing to ensure that they or their partner mechanical or pharmacological contraception during the trial and for 3 months thereafter 6. In the Investigator’s opinion, is able and willing to comply with all trial requirements 7. Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the trial

Exclusion criteria

Exclusion criteria: 1. Female participant who is pregnant, lactating or planning pregnancy during the trial 2. Significant renal or hepatic impairment 3. Scheduled elective procedures requiring general anaesthesia during the trial 4. Any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial 5. Participants who have participated in another research trial involving an investigational product in the past 12 weeks

Design outcomes

Primary

MeasureTime frame
Blood glucose levels, measured using blood samples collected through a venous cannula at baseline and every 15 minutes during two hours

Secondary

MeasureTime frame
Blood alanine and fatty acid levels, measured using blood samples collected through a venous cannula at baseline and every 15 minutes during two hours

Countries

England, United Kingdom

Contacts

Public ContactLuis Adrian Soto Mota
adrian.soto@dpag.ox.ac.uk+44 (0)1865 272 500

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026